Hexarelin — Safety, Research, Risks & Legal Status

Not medical advice. Hexarelin is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	examorelin, hexarelin acetate
Category	Peptide
not_fda_approved	Research chemical only; never approved as a human therapeutic
tolerance_reported	GH response diminishes with repeated use due to GHS-R desensitization
potent_ghs	Considered more potent than GHRP-6 and GHRP-2
US legal status	Hexarelin is not approved by the FDA for human use in the United States and is sold as a research chemical not for human consumption. It has no approved medical indication. It is prohibited at all times in sport under the WADA list as a growth hormone secretagogue.

What is Hexarelin?

Hexarelin is a synthetic hexapeptide growth hormone secretagogue related to GHRP-6 that acts on the ghrelin/GHS receptor to stimulate pituitary release of growth hormone. It has also been studied for direct effects on cardiac tissue through GHS receptors in the heart. Hexarelin is often described as a more potent GHS compound than GHRP-6 and GHRP-2.

How it works

Hexarelin is a GHS-R (ghrelin-receptor) agonist similar to GHRP-6 and GHRP-2, but with reported higher potency and affinity. It stimulates GH release from anterior pituitary somatotrophs via GHS-R activation. Additionally, GHS-R is expressed in myocardial tissue and other tissues, and some research suggests hexarelin may have direct cardiac effects beyond GH stimulation. Repeated dosing may lead to GHS-R desensitization and reduced GH response.

Background & history

Hexarelin was developed in the 1990s as an improved GHS compound with higher potency than earlier GHS peptides. It was studied in both animal models and early human research for GH-secretagogue activity and potential cardiovascular benefits. However, it never gained regulatory approval as a human therapeutic and remains available only as a research chemical.

What the research says

Research, largely from animal models and small early human studies, suggests hexarelin is a potent stimulator of growth hormone release and may have direct cardiovascular effects through GHS receptors in heart tissue. Tolerance to its GH-releasing effect has been reported with repeated dosing, and robust long-term human clinical evidence is limited. Some studies in animal models suggest cardioprotective properties, but human evidence is absent.

Reported effects

Reported potent increase in growth hormone secretion
Studied increases in IGF-1 levels
Reported cardiovascular effects in early research
Reported desensitization of GH release with repeated use
Studied direct effects on cardiac contractility in animal models
Reported stimulation of prolactin in some studies

Dosing & administration (informational)

In research studies, hexarelin has been administered intravenously or subcutaneously in doses ranging from 0.1 to 2 milligrams per kilogram of body weight, with GH peaks observed within 30 to 60 minutes of injection. Some studies examined repeated daily dosing to assess tolerance development over weeks.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Injection carries risks of pain, bruising, infection, and injection-site reactions without sterile technique
Elevated growth hormone and IGF-1 can cause insulin resistance, edema, and joint pain
Increased GH and IGF-1 are a theoretical cancer concern, since IGF-1 promotes cell growth
May raise prolactin and cortisol and can cause GH-axis desensitization with repeated dosing
Prohibited at all times in sport under the WADA list, and research-chemical material may be impure or contaminated
Direct cardiac effects reported in animal research; human cardiovascular safety is not well characterized

Drug & supplement interactions

Somatostatin suppresses hexarelin-induced GH release
Concurrent GHS-R agonists not well-studied; combination effects unpredictable
Cardiovascular drugs (beta-blockers, ACE inhibitors) may interact with cardiac effects
Glucocorticoids can blunt GH response

Who should avoid it

Active malignancy or cancer history (IGF-1 elevation risk)
Known or suspected cardiovascular disease (direct cardiac effects not fully characterized)
Uncontrolled hypertension or arrhythmia
Uncontrolled diabetes
Acute sepsis or critical illness

How it is commonly combined

Hexarelin is not typically combined with other GHS compounds in human use, as synergistic effects and safety of concurrent GHS-R agonists are not well-studied. Combinations would carry compounded risks of desensitization and unpredictable cardiovascular effects.

Legal & regulatory. Hexarelin is not approved by the FDA for human use in the United States and is sold as a research chemical not for human consumption. It has no approved medical indication. It is prohibited at all times in sport under the WADA list as a growth hormone secretagogue.

Quality & harm reduction

R
e
q
u
i
r
e
a
t
h
i
r
d
-
p
a
r
t
y
c
e
r
t
i
f
i
c
a
t
e
o
f
a
n
a
l
y
s
i
s
(
C
O
A
)
f
o
r
a
n
y
p
r
o
d
u
c
t
.
L
o
o
k
f
o
r
H
P
L
C
a
n
d
m
a
s
s
s
p
e
c
t
r
o
m
e
t
r
y
p
u
r
i
t
y
a
n
d
i
d
e
n
t
i
t
y
d
a
t
a
.
E
n
d
o
t
o
x
i
n
(
L
A
L
)
t
e
s
t
i
n
g
m
a
t
t
e
r
s
f
o
r
a
n
y
i
n
j
e
c
t
a
b
l
e
p
e
p
t
i
d
e
.
U
s
e
s
t
e
r
i
l
e
r
e
c
o
n
s
t
i
t
u
t
i
o
n
a
n
d
c
o
l
d
s
t
o
r
a
g
e
t
o
l
i
m
i
t
d
e
g
r
a
d
a
t
i
o
n
a
n
d
p
r
e
s
e
r
v
e
p
e
p
t
i
d
e
s
t
r
u
c
t
u
r
e
.

Lab testing & harm-reduction tools

If you are going to research a compound, verifying identity and purity is the single most protective step. Independent analytical testing and sterile-handling supplies reduce risk.

Compare testing options

Frequently asked questions

Does hexarelin keep working with repeated use?

Research reports that the growth hormone response can diminish over time with continued dosing, a phenomenon described as desensitization.

Is hexarelin legal in the US?

It is not FDA-approved for human use and is sold only as a research chemical. It is also banned in sport.

What dose should I use?

We do not provide human dosing guidance for unapproved research chemicals.

What are the cardiac effects of hexarelin?

Animal research suggests potential direct effects on heart tissue via GHS receptors, but human cardiovascular effects are not well characterized and remain largely unknown.

Why does hexarelin tolerance develop?

Repeated GHS-R activation may cause receptor desensitization, reducing the magnitude of GH secretion with continued dosing.

References & further reading

PubMed: hexarelin growth hormone secretion GHS
PubMed: hexarelin cardiac effects GHS receptor
PubMed: hexarelin desensitization tolerance
WADA Prohibited List: growth hormone secretagogues
PubMed: hexarelin examorelin GH secretagogue